Dr Sara Anjomani Virmouni, PhD, FRSB, FHEA is a Senior Lecturer in Biomedical Sciences at Brunel University of London and Head of the Ataxia Research Group and Rare Diseases Network. She obtained her PhD in Biomedical Sciences from Brunel University of London and has over a decade of experience investigating the molecular and cellular mechanisms underlying neurodegenerative and rare diseases, particularly Friedreich's ataxia (FRDA).
Her research focuses on lipid metabolism, sphingolipid biology, mitochondrial dysfunction, oxidative stress, epigenetic regulation and therapeutic development in neurodegenerative disorders. She has led and contributed to nationally and internationally funded projects and is actively involved in collaborations aimed at developing novel therapies for FRDA. Her work has advanced the development of cellular and animal models for studying disease mechanisms and evaluating therapeutic approaches.
Dr Anjomani Virmouni is a Fellow of the Royal Society of Biology (FRSB) and a Fellow of the Higher Education Academy (FHEA). She serves on the editorial boards of several international journals and is Guest Editor of the Biomolecules Special Issue, "Lipid Metabolism in Neurodegeneration: From Molecular Mechanisms to Therapeutic Targeting". She is a Committee Member of the Biochemical Society and has received funding and awards from organisations including the Friedreich's Ataxia Research Alliance (FARA) and Ataxia UK.
Dr Sara Anjomani Virmouni, PhD, FRSB, FHEA is a Senior Lecturer in Biomedical Sciences at Brunel University of London and Head of the Ataxia Research Group and Rare Diseases Network. She obtained her PhD in Biomedical Sciences from Brunel University of London and has over a decade of experience investigating the molecular and cellular mechanisms underlying neurodegenerative and rare diseases, particularly Friedreich's ataxia (FRDA).
Her research focuses on lipid metabolism, sphingolipid biology, mitochondrial dysfunction, oxidative stress, epigenetic regulation and therapeutic development in neurodegenerative disorders. She has led and contributed to nationally and internationally funded projects and is actively involved in collaborations aimed at developing novel therapies for FRDA. Her work has advanced the development of cellular and animal models for studying disease mechanisms and evaluating therapeutic approaches.
Dr Anjomani Virmouni is a Fellow of the Royal Society of Biology (FRSB) and a Fellow of the Higher Education Academy (FHEA). She serves on the editorial boards of several international journals and is Guest Editor of the Biomolecules Special Issue, "Lipid Metabolism in Neurodegeneration: From Molecular Mechanisms to Therapeutic Targeting". She is a Committee Member of the Biochemical Society and has received funding and awards from organisations including the Friedreich's Ataxia Research Alliance (FARA) and Ataxia UK.